spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Wyeth Pharmaceuticals 

 HSMN NewsFeed - 1 Oct 2021
SpinaFX Medical announces Jeff Cambra as CEO
Devices Orthopaedic Neurosurgery Personnel
 HSMN NewsFeed - 12 Sep 2018
Biohaven Appoints Bob Repella to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 16 Oct 2017
Sigilon Therapeutics Introduces Scientific Advisory Board for Guiding Development of Afibromer(TM) Living Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2017
Axovant Strengthens Executive Team with Key Management Appointments
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 31 Mar 2017
Vencerx Therapeutics Announces Appointments of Robert H. Ring, Ph.D. as Chief Executive Officer and Jeffrey Stevenson as Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2017
Syndax Appoints Richard P. Shea as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Dec 2016
Fibrocell Announces Leadership Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2014
Scioderm Names Ronald Nardi, Ph.D. Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2013
Pfizer Inc. Announces FDA Approval of DUAVEE(TM) (conjugated estrogens/ bazedoxifene) for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis [1]
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Oct 2013
KV Pharmaceutical Company Appoints Former Wyeth Pharmaceuticals President, Joe Mahady to Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Aug 2013
ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 25 Jul 2013
Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 12 Jun 2013
Teva Reaches Settlement Agreement with Pfizer and Nycomed Regarding Generic Protonix(R) (Pantoprazole) Tablets
Biopharmaceuticals Litigation
 HSMN NewsFeed - 20 May 2013
Elan Announces Transactions: Decisively Transforming the Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Mar 2013
Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 May 2012
New Biologics Company, Bioventus, Launches with Focus on Active Orthopaedic Healing
Devices Orthopaedic
 HSMN NewsFeed - 15 Sep 2011
Elan Announces Board of Director Changes
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 2 Mar 2011
CorMedix Appoints Mark A. Klausner, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Feb 2011
Versartis Completes $21 Million Series B Financing
Biopharmaceuticals Endocrinology Venture Capital
 HSMN NewsFeed - 21 Jan 2011
Human Genome Sciences Appoints Greg Norden to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals
 HSMN NewsFeed - 30 Sep 2010
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Devices Interventional Cardiology
 HSMN NewsFeed - 2 Sep 2010
Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
Devices Interventional Cardiology
 HSMN NewsFeed - 25 May 2010
NEVO Sirolimus-eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Mar 2010
Proteostasis Therapeutics Announces Additions of Key Executives
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Mar 2010
Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the CYPHER(R) Sirolimus Drug-Eluting Stent over the Endeavor(R) Zotarolimus-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Mar 2010
EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Mar 2010
Catalyst Biosciences Appoints William J. Dawson Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Feb 2010
Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2010
Noven Announces New Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Oct 2009
Cephalon Appoints Bob Repella as Senior Vice President of U.S. Pharmaceutical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Oct 2009
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Oct 2009
CalciMedica Appoints Evelyn Graham to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Sep 2009
Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 15 Sep 2009
Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene
Biopharmaceuticals
 HSMN NewsFeed - 31 Aug 2009
First Patient Enrolled in CYPRESS, a Dual Antiplatelet Therapy Trial with the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Aug 2009
New Delivery System for RELISTOR in Pre-Filled Syringes Submitted for U.S. and European Marketing Approval
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2009
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2009
Enbrel(R) Receives Positive European Recommendations for a New Plaque Psoriasis Treatment Regimen and New Pre-Filled Pen Delivery Device
Biopharmaceuticals Drug Delivery Devices Regulatory
 HSMN NewsFeed - 29 May 2009
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2009
NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Apr 2009
Ligand Announces Approval in Europe of CONBRIZA for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Apr 2009
New Clinical Data at ACC09 Show the CYPHER Sirolimus-eluting Coronary Stent Outperformed TAXUS LIBERTE and ENDEAVOR Stents in Key Outcome Measures
Devices Interventional Cardiology
 HSMN NewsFeed - 7 Apr 2009
Pfizer Announces Operating Structure and Select Senior Leadership Posts to Be Effective Immediately Upon Close of Wyeth Acquisition
Biopharmaceuticals Mergers & Acquisitions Personnel
 HSMN NewsFeed - 26 Mar 2009
Cordis Celebrates 50 Years of Transforming Cardiovascular Care
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2009
FABLYN Approved in Europe for the Treatment of Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Mar 2009
FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Mar 2009
Cordis Corporation Announces Head-to-Head Randomized Clinical Trial Comparing the NEVO Sirolimus-Eluting Coronary Stent to the XIENCE Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Mar 2009
CYPHER Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Six-Year Randomized Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Feb 2009
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Now Approved in the European Union for Treatment of Patients With Diabetes
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 26 Jan 2009
Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Dec 2008
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Dec 2008
Catalyst Biosciences Raises $40 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Nov 2008
CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Nov 2008
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Oct 2008
Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2008
New Study Shows ENBREL(R) (etanercept) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis Patients
Biopharmaceuticals
 HSMN NewsFeed - 1 Oct 2008
Advanced Life Sciences and Wyeth Sign Commercialization Agreement for Cethromycin in Asia Pacific Region
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2008
Findings From Landmark Study Show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 18 Sep 2008
Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 8 Sep 2008
New Recombinant XYNTHA Now Available for Patients with Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals
 HSMN NewsFeed - 4 Sep 2008
Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and Multi-Vessel Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Sep 2008
Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Aug 2008
The CYPHER(R) Sirolimus-eluting Coronary Stent Outperforms the Taxus(R) Stent in People with Diabetes According to Clinical Data in the Journal of the American College of Cardiology
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Aug 2008
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Receives CE Mark Approval for Treatment of Heart Attacks
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 5 Aug 2008
Pharmacopeia Announces Further Reductions to Workforce
Biopharmaceuticals
 HSMN NewsFeed - 16 Jul 2008
Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 9 Jul 2008
European Commission Announces Marketing Authorisation for 50mg Once Weekly Enbrel(R) for Patients With Moderate-to-Severe Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Jul 2008
European Medicines Agency (EMEA) Approves Relistor(TM) The First-in-Class Treatment of Opioid-Induced Constipation (OIC) in Advanced-Illness Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Jul 2008
Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Jun 2008
Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2008
Wyeth Pharmaceuticals Announces Organizational Change
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2008
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 17 Jun 2008
Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Jun 2008
New Data Demonstrates Joint Damage is Inhibited With Wyeth's Biologic Enbrel(R) Plus Methotrexate in Patients With Early Active Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2008
Biogen Idec Names Hans Peter Hasler Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 May 2008
Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2008
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2008
Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 May 2008
New Evidence Advocates the use of Enbrel to Combat and Effectively Control the Debilitating Symptoms of Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2008
New Data Support Routine Childhood Vaccination With PREVENAR in Europe
Biopharmaceuticals
 HSMN NewsFeed - 29 Apr 2008
Neuromed Names Sean Cunliffe Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2008
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Apr 2008
Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2008
MDS Pharma Services Names Teresa Winslow and James Miskel to Senior Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2008
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Mar 2008
Three Year Follow-up Data Suggest Better Outcomes Were Maintained with the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Brachytherapy in Patients with In-Stent Reblockage
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Mar 2008
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Biopharmaceuticals
 HSMN NewsFeed - 17 Mar 2008
Data Presented at International Psoriasis Meeting Support Potential New Role for Biologic Treatment Etanercept in Management of Childhood Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 12 Mar 2008
Wyeth and Progenics Provide Update on Phase 3 Clinical Trial of Intravenous Methylnaltrexone for Postoperative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2008
More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Mar 2008
Curis Announces Conclusion of Hedgehog Agonist Collaboration with Wyeth
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2008
Wyeth to Invest $280 Million to Build State-of-the-Art Nutritional Manufacturing Facility in China
Biopharmaceuticals
 HSMN NewsFeed - 3 Mar 2008
Crucell Announces Vaccine Development Agreement with Wyeth Pharmaceuticals
Biopharmaceuticals
 HSMN NewsFeed - 29 Feb 2008
Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2008
Wyeth Announces Executive Change in Finance Organization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Feb 2008
Pharmacopeia Announces Management Team Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Feb 2008
Wyeth's XYNTHA Approved by FDA for Treatment of Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Feb 2008
New Breakthrough Treatment for Advanced Kidney Cancer Shows 49 Per Cent Higher Survival Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2008
MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2008
Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 30 Jan 2008
Prasco to Distribute Wyeth's Own Generic Versions of Protonix(R) Delayed-Release Tablets
Biopharmaceuticals Generics Distribution
 HSMN NewsFeed - 29 Jan 2008
Wyeth Announces Launch of Own Generic Version of PROTONIX
Biopharmaceuticals Generics
 HSMN NewsFeed - 22 Jan 2008
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jan 2008
GSK Does Not Option XL784 for Further Development
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Jan 2008
New Study Shows Biologic Therapy Enbrel(R) (etanercept) Effective in Treating Psoriasis in Children and Adolescents
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2008
New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2008
Exelixis Announces Senior Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2008
Dr. Laurence Lasky, Ph.D. Joins U.S. Venture Partners
Venture Capital Personnel
 HSMN NewsFeed - 24 Dec 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Dec 2007
Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals' Launch of Generic Pantoprazole in Violation of PROTONIX Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 12 Dec 2007
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 30 Nov 2007
Wyeth Announces Executive Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Nov 2007
Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 15 Nov 2007
Wyeth Announces Election of New Principal Corporate Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Nov 2007
Pooled Analysis of Long-Term Data Suggests Cypher(R) Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits in Patients with Coronary Artery Disease Compared to Bare Metal Stents
 HSMN NewsFeed - 30 Oct 2007
Minnesota Hormone Therapy Lawsuit Dismissed
Biopharmaceuticals Litigation
 HSMN NewsFeed - 24 Oct 2007
FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2007
Adoption of Drug-Eluting Stents Associated with Lower Health Care Costs and Improved Clinical Outcomes
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
New Long-Term Data Suggest Clinical Differences in Safety and Efficacy between CYPHER(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Oct 2007
New Study Shows Excellent Outcomes for CYPHER(R) Sirolimus-Eluting Coronary Stent in Treatment of Completely Blocked Coronary Arteries
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Oct 2007
Cordis Corporation Announces Clinical Studies and Events at TCT 2007
Devices Interventional Cardiology
 HSMN NewsFeed - 15 Oct 2007
Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
Biopharmaceuticals Litigation
 HSMN NewsFeed - 15 Oct 2007
Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 15 Oct 2007
Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Sep 2007
Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Sep 2007
The CYPHER(R) Sirolimus-Eluting Coronary Stent Outperforms the Taxus Stent in Small Coronary Vessels According to New Clinical Data Analysis Published in the Journal of the American College of Cardiology
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Sep 2007
Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2007
New Data Show That GlaxoSmithKline's Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 12 Sep 2007
Flamel Technologies Announces Medusa(R) License Agreement with Wyeth Pharmaceuticals
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 5 Sep 2007
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Sep 2007
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Sep 2007
Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Sep 2007
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Devices Interventional Cardiology
 HSMN NewsFeed - 29 Aug 2007
Wyeth and Progenics Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Aug 2007
GlaxoSmithKline Accelerates Review of Exelixis' XL880
Biopharmaceuticals
 HSMN NewsFeed - 13 Aug 2007
Actavis Receives Approval for Generic Inderal LA Capsules in the U.S.
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 10 Aug 2007
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Aug 2007
Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Aug 2007
AMAG Pharmaceuticals, Inc. Announces Appointment of Lee F. Allen, M.D., Ph.D. as Chief Medical Officer and Senior Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jul 2007
Lybrel, First Low Dose Combination Oral Contraceptive with Unique 365-Day Dosing, Now Available in U.S.
Biopharmaceuticals
 HSMN NewsFeed - 27 Jul 2007
Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Jul 2007
Wyeth Receives Approvable Letter from FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated with Menopause
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jul 2007
Bentley Announces Product Approvals for Generic Pharmaceuticals
Biopharmaceuticals Generics Regulatory
 HSMN NewsFeed - 3 Jul 2007
Wyeth Begins Marketing and Distributing BeneFIX in Europe
Biopharmaceuticals Distribution
 HSMN NewsFeed - 29 Jun 2007
Wyeth Announces Election of Mary Katherine Wold as Senior Vice President, Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2007
Wyeth Announces Election of Greg Norden as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2007
FDA Grants Fast Track Status for HCV-796 for Treatment of Hepatitis C Virus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2007
Barr Announces Tentative Approval for a Generic Version of Effexor(R) Tablets, 25mg, 37.5mg, 50mg, 75mg and 100mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 20 Jun 2007
Plexxikon Expands Management Team and Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Data Presented at ASCO Showed TORISEL Significantly Increased Quality-Adjusted Survival for Patients With Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Progenics and Wyeth Announce FDA Has Accepted For Filing the New Drug Application for Subcutaneous Methylnaltrexone
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2007
FDA Approves Lybrel, First Low Dose Combination Oral Contraceptive Offering Women the Opportunity to Be Period-Free Over Time
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2007
CYPHER(R) Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2007
Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 May 2007
Wyeth Wins Philadelphia Hormone Therapy Trial
Biopharmaceuticals Litigation
 HSMN NewsFeed - 14 May 2007
Wyeth and Progenics Pharmaceuticals Announce Submission of Marketing Application in Europe for the Subcutaneous Formulation of Methylnaltrexone
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2007
Wyeth Chief Financial Officer and Vice Chairman Kenneth J. Martin to Leave the Company
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Apr 2007
Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2007
Wyeth Responds to Special Report Published in New England Journal of Medicine
 HSMN NewsFeed - 18 Apr 2007
Iroko Pharmaceuticals Appoints John Vavricka as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Apr 2007
Exelixis Appoints Experienced Clinician and Scientist to Vice President of Translational Medicine
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Apr 2007
Wyeth Provides Update on FDA Review of the Torisel New Drug Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Apr 2007
Wyeth Completes Purchase of Wyeth K.K. Japan
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Mar 2007
Progenics and Wyeth Announce Submission of New Drug Application for the Subcutaneous Formulation of Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients Receiving Palliative Care
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 30 Mar 2007
Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
Biopharmaceuticals
 HSMN NewsFeed - 29 Mar 2007
Acceleron Pharma Appoints Robert Steininger as Senior Vice President, Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2007
CYPHER(R) Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Five-Year Randomized Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2007
Two-Year Patient Registry Results Support Safety and Efficacy of CYPHER(R) Sirolimus-Eluting Coronary Stent in 'Real World' Uses
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2007
CYPHER(R) Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2007
Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Mar 2007
Cordis Corporation to Emphasize Commitment to Interventional Cardiology at ACC.07
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2007
Exelixis Files IND Application for XL147
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2007
Siemens Medical Solutions Collaborates with Wyeth to Advance Development of New Alzheimer's Therapies
Biopharmaceuticals Radiology Neurology
 HSMN NewsFeed - 1 Mar 2007
European Committee Issued Positive Opinions to Extend Indication for PREVENAR to Include Pneumonia and Otitis Media
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Feb 2007
Wyeth Pharmaceuticals Announces Organizational Change
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Feb 2007
Wyeth Announces Executive Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2007
Multiple Articles in the New England Journal of Medicine Confirm On-Label, Long-Term Safety and Efficacy of the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and MediVas Announce Research Partnership to Develop Advanced Hemophilia Therapies
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Feb 2007
Survey Indicates People with Chronic Moderate to Severe Plaque Psoriasis May Be Under-Treated
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jan 2007
Par Pharmaceutical Receives Approval of Generic Inderal-LA(R)
Biopharmaceuticals Cardiology Generics FDA
 HSMN NewsFeed - 26 Jan 2007
Wyeth Announces Executive Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jan 2007
Wyeth Receives Approvable Letter From FDA for Pristiq (Desvenlafaxine Succinate) for the Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2007
XTL Biopharmaceuticals Announces the In-Licensing of Bicifadine - A Late-Stage Clinical Compound for the Treatment of Neuropathic Pain
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Jan 2007
Wyeth and Solvay Enter Into an Additional Neuroscience Collaboration
Biopharmaceuticals
 HSMN NewsFeed - 10 Jan 2007
Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2007
Exelixis Announces Senior Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2007
Exelixis Signs Co-Development Agreement With Genentech for Small Molecule Oncology Compound
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2006
Wyeth and Progenics Initiate Second Global Phase 3 Trial of Intravenous Methylnaltrexone to Treat Post-operative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2006
FDA Grants Torisel NDA Priority Review Status
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Dec 2006
Bifeprunox Showed Improvement of Symptoms and Maintenance of Stability with Fewer Metabolic Side Effects vs. Placebo in Patients with Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2006
Phase 2 and 3 Clinical Data for Bifeprunox in Patients With Schizophrenia Showed Improvement of Symptoms and Maintenance of Stability With Fewer Metabolic Side Effects Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2006
Neurogen In-licenses Drug Candidate for Parkinson's Disease and Restless Legs Syndrome
Biopharmacetuicals Licensing
 HSMN NewsFeed - 16 Nov 2006
Johnson & Johnson Announces Definitive Agreement to Acquire Conor Medsystems, Inc.
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 16 Nov 2006
Wyeth Announces Executive Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2006
Preliminary Long-Term Clinical Data Show Promising Results for the CYPHER(R) Sirolimus-eluting Coronary Stent in Patients With Multi-Vessel Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Nov 2006
Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2006
ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2006
Inovio Biomedical Grants Wyeth Pharmaceuticals License to Develop Infectious Disease DNA Vaccines
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 6 Nov 2006
Clinical Studies to be Presented at American Heart Association Scientific Sessions Demonstrate Growing Body of Efficacy and Safety Data for the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 2 Nov 2006
Exelixis Suspends Enrollment of New Patients in XL999 Phase II Clinical Trial Program
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2006
New Randomized Clinical Trial Results Show the Cypher(R) Sirolimus-Eluting Coronary Stent Outperformed the Taxus Stent in Long Coronary Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Oct 2006
Wyeth Responds to Mistrial in Philadelphia Hormone Therapy Case
Biopharmaceuticals Litigation
 HSMN NewsFeed - 6 Oct 2006
Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2006
Biotica Enters into a Research and License Agreement with Wyeth for Novel Rapamycin Analogs
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Oct 2006
Plexxikon and Roche Enter Partnership to Develop Targeted Cancer Therapeutic Medicine PLX4032
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2006
Data Suggest Different Outcomes Between The CYPHER(R) Sirolimus-Eluting Coronary Stent and the Taxus Stent In 'Real World' Settings and Small Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Oct 2006
Plexxikon Files IND Application for Targeted Cancer Therapeutic PLX4032
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
Plexxikon and Servier Signed Cardiovascular Collaboration
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2006
Wyeth Board Adopts Corporate Governance Changes
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2006
Wyeth Announces the Election of Raymond J. McGuire to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Sep 2006
Plexxikon Appoints Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Sep 2006
Progenics and Wyeth Initiate Global Phase 3 Clinical Program of Intravenous Methylnaltrexone to Treat Post-Operative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2006
King Pharmaceuticals Reports DREAM Data on Ramipril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Sep 2006
Study in New England Journal of Medicine Suggests Heart Attack Patients Fare Better with CYPHER(R) Sirolimus-eluting Coronary Stents Than Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Sep 2006
Data Suggest the Cypher(R) Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared to Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Jul 2006
Wyeth and Progenics Announce Methylnaltrexone Receives FDA Fast Track Designation for Treatment of Postoperative Ileus
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jul 2006
King Pharmaceuticals and Wyeth Announce Restructuring of Co-Promotion Agreement for ALTACE(R)
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2006
Wyeth Receives Approvable Letter From the FDA for Lybrel
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2006
Wyeth Submits Two New Drug Applications for Women's Health Therapies
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2006
Cordis Corporation's Third-Generation Coronary Stent Approved for Use in Europe
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 25 May 2006
Desvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement in Symptoms of Depression in Adult Patients Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
New Study Reports Venlafaxine Extended Release May Help Adult Patients Prevent New Episodes of Depression for Up to Two Years
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Topical Hedgehog Agonist Accelerates Wound Healing in Diabetes
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 17 May 2006
Cordis Corporation Submits Pre-Market Approval Supplement for Direct Stenting
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 16 May 2006
Study Suggests Drug-Eluting Stent Type and Vessel Size are Important Predictors of Reblockage in Coronary Artery
Devices Interventional Cardiology
 HSMN NewsFeed - 16 May 2006
Wyeth Announces New Head of Corporate Diversity Effort
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2006
Patient Registry to Evaluate Long-Term Safety and Efficacy of Cordis Next Generation Drug-Eluting Coronary Stents in Clinical Practice
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2006
Cordis Corporation Submits Pre-Market Approval Submission for Reblockage in Coronary Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 9 May 2006
YM Biosciences completes acquisition of Eximias
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 8 May 2006
Wyeth Comments on New Report From The Nurses' Health Study Published Today in the Archives of Internal Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 May 2006
PDI Announces Appointment of Michael J. Marquard as Chief Executive Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 195

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 195 additional stories matching:
Wyeth Pharmaceuticals
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.